Articles avec mandats d'accès public - Gerard DrewesEn savoir plus
Non disponibles : 5
Chemoproteomics and chemical probes for target discovery
G Drewes, S Knapp
Trends in biotechnology 36 (12), 1275-1286, 2018
Exigences : German Research Foundation
Discovery of a highly selective tankyrase inhibitor displaying growth inhibition effects against a diverse range of tumor derived cell lines
DW Thomson, AJ Wagner, M Bantscheff, RE Benson, L Dittus, ...
Journal of Medicinal Chemistry 60 (13), 5455-5471, 2017
Exigences : Federal Ministry of Education and Research, Germany
Clinically relevant OATP2B1 inhibitors in marketed drug space
MS Unger, J Mudunuru, M Schwab, C Hopf, G Drewes, AT Nies, ...
Molecular pharmaceutics 17 (2), 488-498, 2019
Exigences : Federal Ministry of Education and Research, Germany
Interactions of MAP/microtubule affinity regulating kinases with the adaptor complex AP‐2 of clathrin‐coated vesicles
G Schmitt‐Ulms, D Matenia, G Drewes, EM Mandelkow
Cell motility and the cytoskeleton 66 (8), 661-672, 2009
Exigences : German Research Foundation
Direct automated MALDI mass spectrometry analysis of cellular transporter function: inhibition of OATP2B1 uptake by 294 drugs
MS Unger, L Schumacher, T Enzlein, D Weigt, MJ Zamek-Gliszczynski, ...
Analytical Chemistry 92 (17), 11851-11859, 2020
Exigences : German Research Foundation, Federal Ministry of Education and Research, Germany
Disponibles quelque part : 37
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
MA Dawson, RK Prinjha, A Dittmann, G Giotopoulos, M Bantscheff, ...
Nature 478 (7370), 529-533, 2011
Exigences : Cancer Research UK
Tracking cancer drugs in living cells by thermal profiling of the proteome
MM Savitski, FBM Reinhard, H Franken, T Werner, MF Savitski, ...
Science 346 (6205), 1255784, 2014
Exigences : Swedish Research Council
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
L Kruidenier, C Chung, Z Cheng, J Liddle, KH Che, G Joberty, ...
Nature 488 (7411), 404-408, 2012
Exigences : US National Institutes of Health, Instituts de recherche en santé du Canada …
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation
HD Lewis, J Liddle, JE Coote, SJ Atkinson, MD Barker, BD Bax, KL Bicker, ...
Nature chemical biology 11 (3), 189-191, 2015
Exigences : US National Institutes of Health
The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery
HG Stunnenberg, S Abrignani, D Adams, M de Almeida, L Altucci, V Amin, ...
Cell 167 (5), 1145-1149, 2016
Exigences : US National Institutes of Health, UK Biotechnology and Biological Sciences …
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
J Chapuis, F Hansmannel, M Gistelinck, A Mounier, ...
Molecular psychiatry 18 (11), 1225-1234, 2013
Exigences : Fonds de la Recherche Scientifique, Research Foundation (Flanders), Institut …
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
O Gilan, I Rioja, K Knezevic, MJ Bell, MM Yeung, NR Harker, EYN Lam, ...
Science 368 (6489), 387-394, 2020
Exigences : Howard Hughes Medical Institute, National Health and Medical Research …
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
T Paquet, C Le Manach, DG Cabrera, Y Younis, PP Henrich, TS Abraham, ...
Science translational medicine 9 (387), eaad9735, 2017
Exigences : US National Institutes of Health, UK Medical Research Council, Wellcome …
Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition
NH Theodoulou, P Bamborough, AJ Bannister, I Becher, RA Bit, KH Che, ...
Journal of medicinal chemistry 59 (4), 1425-1439, 2016
Exigences : UK Engineering and Physical Sciences Research Council, Wellcome Trust
Biological plasticity rescues target activity in CRISPR knock outs
AH Smits, F Ziebell, G Joberty, N Zinn, WF Mueller, S Clauder-Münster, ...
Nature methods 16 (11), 1087-1093, 2019
Exigences : European Commission
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
UC Okoye-Okafor, B Bartholdy, J Cartier, EN Gao, B Pietrak, AR Rendina, ...
Nature chemical biology 11 (11), 878-886, 2015
Exigences : US National Institutes of Health
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
MA Dawson, EJ Gudgin, SJ Horton, G Giotopoulos, E Meduri, S Robson, ...
Leukemia 28 (2), 311-320, 2014
Exigences : Cancer Research UK, Wellcome Trust, Worldwide Cancer Research, UK
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons
N Ramsden, J Perrin, Z Ren, BD Lee, N Zinn, VL Dawson, D Tam, M Bova, ...
ACS chemical biology 6 (10), 1021-1028, 2011
Exigences : US National Institutes of Health
The frontotemporal dementia mutation R406W blocks tau’s interaction with the membrane in an annexin A2–dependent manner
A Gauthier-Kemper, C Weissmann, N Golovyashkina, Z Sebö-Lemke, ...
Journal of Cell Biology 192 (4), 647-661, 2011
Exigences : German Research Foundation
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
DS Tyler, J Vappiani, T Cañeque, EYN Lam, A Ward, O Gilan, YC Chan, ...
Science 356 (6345), 1397-1401, 2017
Exigences : National Health and Medical Research Council, Australia, European Molecular …
Les informations concernant la publication et le financement sont déterminées automatiquement par un programme informatique